Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

besins healthcare australia pty ltd - estradiol hemihydrate, quantity: 0.06 % w/w (equivalent: estradiol, qty 0.06 % w/w) - gel - excipient ingredients: carbomer 980; trolamine; ethanol; purified water - - hormone replacement therapy (hrt) for estrogen deficiency symptoms in postmenopausal women.,- prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis. (see also section 4.4 special warnings and precautions for use),the experience treating women older than 65 years is limited. the lowest effective dose should be used for the shortest duration (see sections 4.2 dose and method of administration and 4.4 special warnings and precautions for use).

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - escitalopram oxalate, quantity: 25.54 mg (equivalent: escitalopram, qty 20 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; hypromellose; titanium dioxide; microcrystalline cellulose; macrogol 6000; purified talc; croscarmellose sodium; magnesium stearate; lactose monohydrate - treatment of major depression. treatment of obsessive compulsive disorder.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - escitalopram oxalate, quantity: 12.77 mg (equivalent: escitalopram, qty 10 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; purified talc; hypromellose; macrogol 6000; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; lactose monohydrate; titanium dioxide - treatment of major depression. treatment of obsessive compulsive disorder.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

interpharma pty ltd - terlipressin, quantity: 1.7 mg - injection, solution - excipient ingredients: sodium chloride; glacial acetic acid; sodium hydroxide; hydrochloric acid; water for injections - terlipressin ever pharma solution for injection is indicated for the: - treatment of bleeding oesophageal varices; - treatment of patients with hepatorenal syndrome (hrs) type 1 who are actively being considered for liver transplant.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

interpharma pty ltd - terlipressin, quantity: 0.85 mg - injection, solution - excipient ingredients: sodium chloride; glacial acetic acid; sodium hydroxide; hydrochloric acid; water for injections - terlipressin ever pharma solution for injection is indicated for the: - treatment of bleeding oesophageal varices; - treatment of patients with hepatorenal syndrome (hrs) type 1 who are actively being considered for liver transplant.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - tibolone, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; potato starch; ascorbyl palmitate; magnesium stearate; mannitol - - short-term treatment of symptoms resulting from the natural or surgical menopause in postmenopausal women.,- second line therapy for the prevention of bone mineral density loss in postmenopausal women at high risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - tibolone, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: mannitol; lactose monohydrate; magnesium stearate; potato starch; ascorbyl palmitate - - short-term treatment of symptoms resulting from the natural or surgical menopause in postmenopausal women.,- second line therapy for the prevention of bone mineral density loss in postmenopausal women at high risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - tibolone, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: pregelatinised potato starch; ascorbyl palmitate; magnesium stearate; lactose monohydrate; lactose - ? short-term treatment of symptoms resulting from the natural or surgical menopause in postmenopausal women. ? second line therapy for the prevention of bone mineral density loss in postmenopausal women at high risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss. after careful selection of users, <> (tibolone tablets) should be prescribed for the shortest duration consistent with treatment goals. review the need for continuation of treatment after 6 months, taking into account the risk-benefit ratio for the individual user at that moment (including cardiovascular disease and breast cancer, see clinical trials and precautions). <> (tibolone tablets) should only be continued for as long as the benefit outweighs the risks.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - paroxetine hydrochloride, quantity: 22.22 mg (equivalent: paroxetine, qty 20 mg) - tablet, film coated - excipient ingredients: sodium starch glycollate; magnesium stearate; microcrystalline cellulose; mannitol; basic butylated methacrylate copolymer; titanium dioxide; purified talc; polyvinyl alcohol; sodium lauryl sulfate; glyceryl monostearate - treatment of major depression and for the prevention of relapse of depressive symptoms; treatment of obsessive compulsive disorder and for the prevention of relapse of ocd; treatment of panic disorder and for the prevention of relapse of panic disorder; treatment of social anxiety disorder/ social phobia; treatment of generalised anxiety disorder; and treatment of post-traumatic stress disorder

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - escitalopram oxalate, quantity: 25.548 mg - tablet, film coated - excipient ingredients: maize starch; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; mannitol; titanium dioxide; hypromellose; macrogol 6000 - treatment of major depression. ,treatment of social anxiety disorder (social phobia). ,treatment of generalised anxiety disorder. ,treatment of obsessive-compulsive disorder.